A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy

Journal of Surgical Oncology

Volumn 93, Issue 5, 2006, Pages 387-393

  Martin II, Robert C G ^a,b   Scoggins, Charles R ^a   McMasters, Kelly M ^a  

^a University of Louisville School of Medicine   (United States)

^b NONE   (United States)

Author keywords

Hepatic artery infusion; Hepatic artery infusion chemotherapy; Metastatic colorectal cancer; Radiofrequency ablation

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LIVER ENZYME; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CATHETER OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE TIME EFFECT RELATION; DRUG TREATMENT FAILURE; EVALUATION; FEMALE; HEPATIC ARTERY; HUMAN; INFUSION PUMP; INFUSION PUMP OCCLUSION; LIVER ABSCESS; LIVER DYSFUNCTION; LIVER METASTASIS; MALE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SUBCLAVIAN VEIN; SURVIVAL RATE; VEIN THROMBOSIS; ADJUVANT CHEMOTHERAPY; CATHETER ABLATION; COLORECTAL TUMOR; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATIC ARTERY; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; UNITED STATES;

EID: 33646167674     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20463     Document Type: Article

References (38)

1. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318.
2. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825.
3. Curley SA, Izzo F, Delrio P, et al.: Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 1999;230:1-8.
4. Wood TF, Rose DM, Chung M, et al.: Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 2000;7:593-600.
5. Bowles BJ, Machi J, Limm WM, et al.: Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg 2001;136:864-869.
6. De Baere T, Elias D, Dromain C, et al.: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-1625.
7. Solbiati L, Livraghi T, Goldberg SN, et al.: Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: Long-term results in 117 patients. Radiology 2001;221:159-166.
8. Sullivan RD, Norcross JW, Watkins E: Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med 1964;270:321-327.
9. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-2048.
10. Onaitis M, Morse M, Hurwitz H, et al.: Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg 2003;237:782-788.
11. Kesmodel SB, Canter RJ, Raz DJ, et al.: Survival following regional treatment for metastatic colorectal cancer to the liver using radiofrequency ablation and hepatic infusion pump placement. The Society of Surgical Oncology, 55th Annual Cancer Symposium, Denver, CO. 2002.
12. Scaife CL, Curley SA, Izzo F, et al.: Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 2003;10:348-354.
13. Couinaud C: Le foie: Etudes anatomiques et Chirurgicales. Paris: Masson & Cie; 1957.
14. Kemeny N, Conti JA, Cohen A, et al.: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12:2288-2295.
15. Martin RC, Jarnagin WR, Fong Y, et al.: The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: Is there a standard for transfusion? J Am Coll Surg 2003;196:402-409.
16. Martin RC, Edwards MJ, McMasters KM: Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver. Am J Surg 2004;188:714-721.
17. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
18. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825.
19. Ambiru S, Miyazaki M, Ito H, et al.: Adjuvant regional chemotherapy after hepatic resection for colorectal metastases. Br J Surg 1999;86:1025-1031.
20. Weber SM, Jarnagin WR, DeMatteo RP, et al.: Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000;7:643-650.
21. Elias D, Sideris L, Pocard M, et al.: Results of RO resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274-280.
22. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
23. de Gramont A, Vignoud J, Tournigand C, et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
24. Andre T, Louvet C, Raymond E, et al.: Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251-1253.
25. Maindrault-Goebel F, Louvet C, Andre T, et al.: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-1342.
26. Andre T, Bensmaine MA, Louvet C, et al.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
27. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11:1477-1483.
28. Maindrault-Goebel F, de Gramont A, Louvet C, et al.: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000-1005.
29. Machi J: Radiofrequency ablation for multiple hepatic metastases. Ann Surg Oncol 2001;8:379-380.
30. Siperstein A, Garland A, Engle K, et al.: Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7:106-113.
31. Curley SA, Izzo F: Laparoscopic radiofrequency. Ann Surg Oncol 2000;7:78-79.
32. Kemeny MM, Adak S, Gray B, et al.: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-An intergroup study. J Clin Oncol 2002;20:1499-1505.
33. Lorenz M, Muller HH, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998;228:756-762.
34. Martin JK, Jr., O'Connell MJ, Wieand HS, et al.: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990;125:1022-1027.
35. Rougier P, Laplanche A, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-1118.
36. Allen-Mersh TG, Earlam S, Fordy C, et al.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-1260.
37. Kemeny N, Daly J, Reichman B, et al.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-465.
38. Kemeny MM, Adak S, Gray B, et al.: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-An intergroup study. J Clin Oncol 2002;20:1499-1505.